RxDoctor Payments Data

Venu Gourineni, MD

Cardiovascular Disease · Canton, GANPI 1154473635

Payments from drug & device makers

$1,939in general payments, 2019–2025

Across 61 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$526
  • Novartis$340
  • Heartflow, Inc.$273
  • Edwards Lifesciences$144
  • Bolton Medical Inc$128
  • E.r. Squibb & Sons, L.L.C.$88
  • plus $440 from 13 others

What the payments were for

  • Travel & lodging$24513%
  • Food & beverage$1,69387%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,939 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$102,777
Medicare patients
814
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban331$383,897
EntrestoSacubitril/Valsartan226$251,984
XareltoRivaroxaban181$210,976
FarxigaDapagliflozin Propanediol105$108,751
JardianceEmpagliflozin38$45,608
Repatha SureclickEvolocumab42$26,992
Metoprolol Succinate912$16,661
Atorvastatin Calcium712$12,612
BrilintaTicagrelor12$11,759
Ranolazine ErRanolazine108$11,516
Isosorbide Dinitrate132$10,466
Isosorbide Mononitrate ErIsosorbide Mononitrate327$7,868
Bumetanide241$7,533
Propafenone Hcl ErPropafenone Hcl18$4,699
ClopidogrelClopidogrel Bisulfate230$4,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$340$251,984226 claims
Johnson & JohnsonXarelto$15$210,976181 claims
AstraZenecaFarxiga, Brilinta$13$120,511117 claims
Boehringer IngelheimJardiance$23$45,60838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →